| 0.4865 -0.002 (-0.39%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.71 | 1-year : | 0.84 |
| Resists | First : | 0.61 | Second : | 0.72 |
| Pivot price | 0.49  |
|||
| Supports | First : | 0.44 | Second : | 0.37 |
| MAs | MA(5) : | 0.48 |
MA(20) : | 0.5 |
| MA(100) : | 1.13 |
MA(250) : | 3.26 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 31.9 |
D(3) : | 30.8 |
| RSI | RSI(14): 36.9 |
|||
| 52-week | High : | 8.68 | Low : | 0.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BIVI ] has closed above bottom band by 43.7%. Bollinger Bands are 91.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.51 - 0.51 | 0.51 - 0.51 |
| Low: | 0.47 - 0.48 | 0.48 - 0.48 |
| Close: | 0.48 - 0.49 | 0.49 - 0.49 |
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
Thu, 18 Apr 2024
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with ... - Yahoo Canada Finance
Tue, 26 Mar 2024
Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders ... - PR Newswire
Tue, 12 Mar 2024
Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now - Yahoo Finance
Mon, 04 Mar 2024
Why Is BioVie (BIVI) Stock Down 41% Today? - InvestorPlace
Fri, 01 Mar 2024
BioVie stock jumps on presentations about Alzheimer's drug - Seeking Alpha
Fri, 01 Mar 2024
BioVie Inc. Announces Proposed Public Offering of Common Stock - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 43.2 (%) |
| Held by Institutions | 4.4 (%) |
| Shares Short | 1,480 (K) |
| Shares Short P.Month | 1,020 (K) |
| EPS | -1.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -80.9 % |
| Return on Equity (ttm) | -257.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -41 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -0.42 |
| PEG Ratio | 0 |
| Price to Book value | 2.56 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|